Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax Vaccine
Biopharm company awarded $80.3M contract for anthrax vaccine candidate
October 27th, 2003
VaxGen, Inc., (VXGN) has been awarded an $80.3 million contract from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) for the advanced development of its anthrax vaccine candidate, rPA102. The 3-year contract is intended to fund many of the steps required for commercial licensure of the vaccine candidate and could pave the way for a significantly larger contract for a national stockpile of anthrax vaccine. "We are pleased to have been awarded a contract that plays such an important role in our nation's defense," said Lance K. Gordon, PhD, VaxGen's chief executive officer. "We believe we were awarded this...
Source: Health & Medicine Week (2003-10-27)
|
